New research reveals connection between drug treatments and antimicrobial resistance in cattle disease
BY Kansas State Research and Extension (K-State)
via KTIC (NE) - January 9, 2020
MANHATTAN — A new study from Kansas State University on the treatment of non-responding cases of bovine respiratory disease, known as BRD, conducted by Hans Coetzee and his collaborators from Iowa State University, sheds light on the relationship between drug treatments and the emergence of antimicrobial resistance.
The study, “Association between antimicrobial drug class for treatment and retreatment of bovine respiratory disease (BRD) and frequency of resistant BRD pathogen isolation from veterinary diagnostic laboratory samples,” was published in the December 2019 issue of the journal PLOS ONE.
“Bovine respiratory disease is one of the most important diseases facing beef cattle producers in the United States with economic losses estimated to approach $1 billion a year,” Coetzee said. “Antibiotics are critical to minimize losses associated with BRD caused by bacterial infections.”
Antibiotics that are used to treat BRD are broadly classified into two groups: namely those that prevent growth of the bacteria — i.e., bacteriostatic — and those that kill the organism — i.e., bactericidal. Although 90% of BRD relapses are reported to receive retreatment with a different class of antimicrobial, the impact of antibiotic selection — bactericidal or bacteriostatic — on disease outcomes and the emergence of antimicrobial resistance has not been investigated, according to Coetzee.
The focus of the study is determining the association between antimicrobial class selection for treatment and retreatment of BRD relapses and antimicrobial susceptibility of Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Pathogens were isolated from samples submitted to the Iowa State University Veterinary Diagnostic Laboratory...